List view / Grid view

Leila Jaafar-Thiel (Nuclidium AG)

 

article

Meeting rising demands of a new radiotheranostic era

Targeted radiotheranostics are on the path to becoming integral to…

31 August 2023 | By

Targeted radiotheranostics are on the path to becoming integral to cancer diagnosis and treatment. Their success, however, depends on patient benefit and the ability to meet commercial demands for broader indications. Aside from the therapeutic or diagnostic efficacy, decisions on suitable radionuclide properties and owning the supply chain will be…